Quick Answer
SUPERNUS PHARMACEUTICALS, INC. reported Diluted EPS of $0.68 per share (loss) for fiscal year 2025.
SUPERNUS PHARMACEUTICALS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.68 | -151.5% |
| 2024 | $1.32 | +6500.0% |
| 2023 | $0.02 | -98.1% |
| 2022 | $1.04 | +6.1% |
| 2021 | $0.98 | -58.5% |
| 2020 | $2.36 | +12.4% |
| 2019 | $2.10 | +2.4% |
| 2018 | $2.05 | +89.8% |
| 2017 | $1.08 | -38.6% |
| 2016 | $1.76 | +528.6% |
| 2015 | $0.28 | +207.7% |
| 2014 | -$0.26 | +91.0% |
| 2013 | -$2.90 | -6.6% |
| 2012 | -$2.72 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.80 | -215.9% | -300.0% |
| June 30, 2025 | $0.40 | +11.1% | +290.5% |
| March 31, 2025 | -$0.21 | — | -130.4% |
| September 30, 2024 | $0.69 | +337.9% | +91.7% |
| June 30, 2024 | $0.36 | +1900.0% | — |
| March 31, 2024 | $0.00 | -100.0% | +100.0% |
| September 30, 2023 | -$0.29 | -1066.7% | -1350.0% |
| June 30, 2023 | -$0.02 | -114.3% | -106.9% |
- SUPERNUS PHARMACEUTICALS, INC. showed a decrease of -151.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2012–2025 period, SUPERNUS PHARMACEUTICALS, INC.’s diluted eps has grown by 75.0% (from $2.72 per share (loss) to $0.68 per share (loss)).
- The most recent figure is from SUPERNUS PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: